-
1
المؤلفون: Brent C. Opmeer, Katja N. Gaarenstroom, Mirjam J. A. Engelen, M. Caroline Vos, Christiana A. Naaktgeboren, Kees G. Gerestein, Patrick M.M. Bossuyt, Ben W.J. Mol, Anje M. Spijkerboer, Guus Fons, Toon Van Gorp, Petra L.M. Zusterzeel, Henk W.R. Schreuder, Hannah S. van Meurs, Eltjo M.J. Schutter, Roelien van de Vrie, Henk G. ter Brugge, Gemma G. Kenter, Maarten van Haaften, Ward Hofhuis, Erik A. Boss, Marrije R. Buist, Johanna M.A. Pijnenborg, Henriette J. G. Arts, Marianne J. Rutten
المساهمون: Targeted Gynaecologic Oncology (TARGON), CCA -Cancer Center Amsterdam, Obstetrics and Gynaecology, CCA - Cancer Treatment and Quality of Life, Graduate School, APH - Methodology, Clinical Research Unit, ACS - Amsterdam Cardiovascular Sciences, Other Research, Radiology and Nuclear Medicine, APH - Personalized Medicine, 10 Public Health & Methodologie, APH - Quality of Care, ARD - Amsterdam Reproduction and Development, Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), RS: GROW - R2 - Basic and Translational Cancer Biology, Gynaecologie en Obstetrie
المصدر: Journal of Clinical Oncology, 35(6), 613-621. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 35(6), 613. American Society of Clinical Oncology
Journal of clinical oncology, 35(6):6, 613-621. American Society of Clinical Oncology
Journal of Clinical Oncology, 35, 6, pp. 613-621
Journal of Clinical Oncology, 35(6), 613
Journal of Clinical Oncology, 35, 613-621
Journal of Clinical Oncology, 35(6), 613-621. American Society of Clinical Oncologyمصطلحات موضوعية: EXTERNAL VALIDATION, Cancer Research, Neoplasm, Residual, medicine.medical_treatment, Carcinoma, Ovarian Epithelial, law.invention, NEOADJUVANT CHEMOTHERAPY, 0302 clinical medicine, Randomized controlled trial, law, Laparotomy, Neoplasms, Glandular and Epithelial, Laparoscopy, Ovarian Neoplasms, RISK, 030219 obstetrics & reproductive medicine, medicine.diagnostic_test, Middle Aged, INTERVAL DEBULKING SURGERY, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Multicenter Study, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Predictive value of tests, Randomized Controlled Trial, SURGICAL CYTOREDUCTION, Female, medicine.medical_specialty, CARCINOMA, ADNEX MODEL, Disease-Free Survival, 03 medical and health sciences, Predictive Value of Tests, SCORE, Journal Article, medicine, Carcinoma, Humans, Aged, Neoplasm Staging, STAGE III/IV OVARIAN, Chemotherapy, business.industry, General surgery, medicine.disease, Surgery, Relative risk, Ovarian cancer, business, ABDOMINAL-WALL METASTASES
الوصف: Purpose To investigate whether initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery (PCS) by identifying patients with advanced-stage ovarian cancer in whom > 1 cm of residual disease will be left after PCS. Patients and Methods This multicenter, randomized controlled trial was undertaken within eight gynecologic cancer centers in the Netherlands. Patients with suspected advanced-stage ovarian cancer who qualified for PCS were eligible. Participating patients were randomly assigned to either laparoscopy or PCS. Laparoscopy was used to guide selection of primary treatment: either primary surgery or neoadjuvant chemotherapy followed by interval surgery. The primary outcome was futile laparotomy, defined as a PCS with residual disease of > 1 cm. Primary analyses were performed according to the intention-to-treat principle. Results Between May 2011 and February 2015, 201 participants were included, of whom 102 were assigned to diagnostic laparoscopy and 99 to primary surgery. In the laparoscopy group, 63 (62%) of 102 patients underwent PCS versus 93 (94%) of 99 patients in the primary surgery group. Futile laparotomy occurred in 10 (10%) of 102 patients in the laparoscopy group versus 39 (39%) of 99 patients in the primary surgery group (relative risk, 0.25; 95% CI, 0.13 to 0.47; P < .001). In the laparoscopy group, three (3%) of 102 patients underwent both primary and interval surgery compared with 28 (28%) of 99 patients in the primary surgery group ( P < .001). Conclusion Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer. In women with a plan for PCS, these data suggest that performance of diagnostic laparoscopy first is reasonable and that if cytoreduction to < 1 cm of residual disease seems feasible, to proceed with PCS.
وصف الملف: image/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88afffec900de1bc3a3271a3325055c3
https://doi.org/10.1200/jco.2016.69.2962 -
2
المؤلفون: Maarten van Haaften, Marrije R. Buist, Marianne J. Rutten, Ward Hofhuis, Katja N. Gaarenstroom, Erik A. Boss, Brent C. Opmeer, Eltjo M.J. Schutter, Mirjam J. A. Engelen, Ben W.J. Mol, Kees G. Gerestein, Hannah S. van Meurs, Henriette J. G. Arts, Henk W.R. Schreuder, Gemma G. Kenter, M. Caroline Vos, Johanna M.A. Pijnenborg, Henk G. ter Brugge, Roelien van de Vrie, Christiana A. Naaktgeboren, Patrick M.M. Bossuyt, Toon Van Gorp, Petra L.M. Zusterzeel
المساهمون: CCA - Cancer Treatment and Quality of Life, Graduate School, Obstetrics and Gynaecology, Cancer Center Amsterdam, APH - Methodology, Clinical Research Unit, APH - Personalized Medicine, Epidemiology and Data Science, APH - Quality of Care, Amsterdam Reproduction & Development (AR&D), Targeted Gynaecologic Oncology (TARGON), Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), RS: GROW - R2 - Basic and Translational Cancer Biology, Gynaecologie en Obstetrie, Obstetrics and gynaecology, CCA - Cancer Treatment and quality of life
المصدر: van de Vrie, R, van Meurs, H S, Rutten, M J, Naaktgeboren, C A, Opmeer, B C, Gaarenstroom, K N, van Gorp, T, Ter Brugge, H G, Hofhuis, W, Schreuder, H W R, Arts, H J G, Zusterzeel, P L M, Pijnenborg, J M A, van Haaften, M, Engelen, M J A, Boss, E A, Vos, M C, Gerestein, K G, Schutter, E M J, Kenter, G G, Bossuyt, P M M, Mol, B W & Buist, M R 2017, ' Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer ', Gynecologic Oncology, vol. 146, no. 3, pp. 449-456 . https://doi.org/10.1016/j.ygyno.2017.06.019
Gynecologic Oncology, 146, 3, pp. 449-456
Gynecologic oncology, 146(3), 449-456. Academic Press Inc.
Gynecologic Oncology, 146, 449-456
Gynecologic Oncology, 146(3), 449-456
Gynecologic Oncology, 146(3), 449-456. ACADEMIC PRESS INC ELSEVIER SCIENCE
Gynecologic Oncology, 146(3), 449. Academic Press Inc.
Gynecologic Oncology, 146(3), 449-456. Elsevier Science
Gynecologic Oncology, 146(3), 449-456. Academic Press Inc.مصطلحات موضوعية: Cost effectiveness, PREDICTION, medicine.medical_treatment, Cost-Benefit Analysis, law.invention, NEOADJUVANT CHEMOTHERAPY, 0302 clinical medicine, Obstetrics and gynaecology, Randomized controlled trial, Quality of life, law, QUALITY-OF-LIFE, Health care, Obstetrics and Gynaecology, Cytoreductive surgery, 030212 general & internal medicine, Laparoscopy, Neoadjuvant therapy, Ovarian Neoplasms, medicine.diagnostic_test, Obstetrics and Gynecology, Cytoreduction Surgical Procedures, Health Care Costs, Middle Aged, Neoadjuvant Therapy, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], TRIALS, Oncology, Diagnostic Techniques, Surgical, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Quality-Adjusted Life Years, Medical Futility, medicine.medical_specialty, Diagnostic laparoscopy, 03 medical and health sciences, Ovarian cancer, medicine, Journal Article, Humans, PRIMARY DEBULKING SURGERY, Neoplasm Staging, business.industry, General surgery, ONCOLOGY, PHASE-III, Quality-adjusted life year, Cost-effectiveness, business
الوصف: Objective. To evaluate the cost-effectiveness of a diagnostic laparoscopy prior to primary cytoreductive surgery to prevent futile primary cytoreductive surgery (i.e. leaving >1 cm residual disease) in patients suspected of advanced stage ovarian 'cancer.Methods. An economic analysis was conducted alongside a randomized controlled trial in which patients suspected of advanced stage ovarian cancer who qualified for primary cytoreductive surgery were randomized to either laparoscopy or primary cytoreductive surgery. Direct medical costs from a health care perspective over a 6-month time horizon were analyzed. Health outcomes were expressed in quality-adjusted life-years (QALYs) and utility was based on patient's response to the EQ-5D questionnaires. We primarily focused on direct medical costs based on Dutch standard prices.Results. We studied 201 patients, of whom 102 were randomized to laparoscopy and 99 to primary cytoreductive surgery. No significant difference in QALYs (utility = 0.01; 95% CI 0.006 to 0.02) was observed. Laparoscopy reduced the number of futile laparotomies from 39% to 10%, while its costs were (sic) 1400 per intervention, making the overall costs of both strategies comparable (difference (sic) - 80 per patient (95% CI - 470 to 300)). Findings were consistent across various sensitivity analyses.Conclusion. In patients with suspected advanced stage ovarian cancer, a diagnostic laparoscopy reduced the number of futile laparotomies, without increasing total direct medical health care costs, or adversely affecting complications or quality of life. (C) 2017 Elsevier Inc. All rights reserved.
وصف الملف: image/pdf; application/pdf
-
3
المؤلفون: Annerie Slot, Marika C. Stenfert Kroese, Astrid N. Scholten, Sabine Siesling, Job van der Palen, Elzbieta van der Steen-Banasik, Eltjo M.J. Schutter, Lambert Naudin ten Cate, Jan J. Jobsen, Marnix L.M. Lybeert
المساهمون: Faculty of Behavioural, Management and Social Sciences
المصدر: Gynecologic oncology, 117(1), 32-36. Academic Press
مصطلحات موضوعية: Oncology, Adult, medicine.medical_specialty, Prognostic factor, Cell type, Multivariate analysis, Disease-Free Survival, Internal medicine, Carcinoma, Medicine, Humans, Neoplasm Metastasis, Aged, Neoplasm Staging, Aged, 80 and over, business.industry, Hazard ratio, IR-77364, Obstetrics and Gynecology, Middle Aged, medicine.disease, Combined Modality Therapy, Peritoneal washing, Endometrial Neoplasms, METIS-271536, Female, Stage IIIa, Neoplasm Recurrence, Local, business, Carcinoma, Endometrioid
الوصف: The aim of this study was to look at the impact of the number of sites with tumour involvement on outcome for patients with stage IIIA endometrioid-type endometrial carcinoma. Patients and methods: 141 patients stage IIIA were included. A central histopathological review was performed. Patients staged solely on the presence of a positive peritoneal washing were excluded. Follow-up ranged from 2 to 217 months with a median of 43 months. Endpoints of the study were locoregional recurrence rates, distant metastasis-free survival (DMFS), disease-free survival (DFS) and disease-specific survival (DSS). Results: In multivariate analyses the number of involved sites showed to be the only independent significant variable for DMFS, DFS, and DSS with a Hazard Ratio of 2.1, 2.2, and 2.2, respectively. The DSS was significantly related to the number of involved sites, with a 5-year DSS of 70.4% for one site, 42.8% for two sites, and 43.9% for three sites, respectively (p = 0.001). Conclusion: The number of involved sites outside the corpus uterine for stage IIIA seems to be a strong negative prognostic factor for stage IIIA endometrial carcinoma.
-
4
المؤلفون: Eltjo M.J. Schutter, Rob van der Sijde
المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 24(7)
مصطلحات موضوعية: Male, medicine.medical_specialty, Groin, business.industry, General surgery, Liver Neoplasms, Obstetrics and Gynecology, Antibodies, Monoclonal, Vulvar cancer, Sentinel node, Adenocarcinoma, medicine.disease, Surgery, medicine.anatomical_structure, Oncology, Antineoplastic Combined Chemotherapy Protocols, Original Reports, medicine, Humans, Female, business
-
5
المؤلفون: Philip Kuijper, Annelie J.E Vulink, Lambert Naudin ten Cate, Eltjo M.J. Schutter, Istvan Vermes
المصدر: European Journal of Obstetrics & Gynecology and Reproductive Biology. 112:221-227
مصطلحات موضوعية: Adult, Steroid cell tumour, medicine.medical_specialty, Ovariectomy, Pregnancy, High-Risk, Gestational Age, Ultrasonography, Prenatal, Pregnancy, Humans, Sex Cord-Gonadal Stromal Tumors, Medicine, Ovarian tumours, Fetal Death, Ovarian Neoplasms, Gynecology, business.industry, Obstetrics, Pregnant patient, Biopsy, Needle, fungi, Not Otherwise Specified, Pregnancy Outcome, Obstetrics and Gynecology, medicine.disease, Immunohistochemistry, Magnetic Resonance Imaging, Virilism, Work-up, Reproductive Medicine, Gestation, Female, Steroids, Differential diagnosis, business, Pregnancy Complications, Neoplastic, Maternal Age
الوصف: Steroid cell tumours not otherwise specified are rare ovarian tumours, which can cause foetal and maternal virilisation. This is the first case report that describes a steroid cell tumour not otherwise specified during pregnancy. Differential diagnosis, a diagnostic work-up and treatment are discussed.
-
6
المؤلفون: Silvia von Mensdorff-Pouilly, Rob A. Verstraeten, Peter Kenemans, Eltjo M.J. Schutter, Elvira M. Davelaar, Gerard J. van Kamp
المصدر: Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 40:663-673
مصطلحات موضوعية: medicine.medical_specialty, Pathology, endocrine system diseases, Clinical Biochemistry, Endometriosis, Sensitivity and Specificity, Gastroenterology, Immunoscintigraphy, Ovarian disease, Internal medicine, CA125-II Assay, Biomarkers, Tumor, medicine, Humans, Immunoassay, Ovarian Neoplasms, medicine.diagnostic_test, biology, business.industry, Intracellular Signaling Peptides and Proteins, Technical evaluation, Proteins, General Medicine, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, biology.protein, Female, Antibody, Ovarian cancer, business
الوصف: Background: In this study the clinical and technical performance of the CA125- detecting Bayer ACS:OV immunoluminometric serum assay was compared with three other well-established CA125-detecting assays. Methods: A total of 1112 serum samples was included in this evaluation: 462 from apparently healthy women, 153 from patients with benign ovarian disease, 163 from patients with malignant ovarian disease, 10 from patients with borderline ovarian malignancies and 78 samples from 12 ovarian cancer patients during monitoring of disease. Serum samples from women with malignant endometrial ( n = 68) and colon ( n = 32) diseases were also included. Moreover, serum samples from women with benign uterine disease and endometriosis ( n = 136) plus 10 serum samples from men ( n = 7) and women ( n = 3) with human anti-mouse antibodies (HAMA) after immunoscintigraphy were included. All samples were tested in duplicate with the Bayer ACS:OV, the Centocor CA125 II, the Abbott IMx CA125 and the Roche (formerly Boehringer Mannheim) Enzymun-Test® CA125 II assays. Results: The clinical performance of the Bayer ACS:OV assay, assessed in various patient groups, was similar to that of the two other automated assays. In serum from patients with benign diseases the highest values were found in patients with benign ovarian tumours. In the ovarian cancer patients followed during the course of disease we found similar marker patterns with all four assays. In contrast to the Roche Enzymun-CA125 II assay and to a lesser extent the Centocor CA125 II assay, the Bayer ACS:OV assay was less sensitive to interference from HAMA. Conclusion: The Bayer ACS:OV assay is a precise and reliable test for the quantification of CA125 in serum.
-
7
المؤلفون: Eltjo M.J. Schutter, Elvira M. Davelaar, Gerard J. van Kamp, P. Kenemans, René H.M. Verheijen, Rob A. Verstraeten
المصدر: American Journal of Obstetrics and Gynecology. 187:385-392
مصطلحات موضوعية: Adult, medicine.medical_specialty, Pathology, Genital Neoplasms, Female, CA 15-3, Malignancy, Sensitivity and Specificity, Gastroenterology, Diagnosis, Differential, Predictive Value of Tests, Ovarian carcinoma, Internal medicine, medicine, Carcinoma, Humans, Antigens, Tumor-Associated, Carbohydrate, Aged, Retrospective Studies, Tumor marker, Aged, 80 and over, business.industry, Mucin-1, Obstetrics and Gynecology, Middle Aged, Pelvic cavity, medicine.disease, medicine.anatomical_structure, ROC Curve, CA-125 Antigen, Concomitant, Predictive value of tests, Female, business
الوصف: The purpose of this study was to assess the differential diagnostic potential of a combination of CA 125, CA 15-3, and CA 72-4 antigens in the definition of malignant disease, especially ovarian carcinoma in patients with a pelvic mass.A total of 412 patients were evaluated in a multicenter, retrospective study.Two hundred twenty-six malignant, 171 benign pelvic tumors (of which 129 were benign ovarian tumors), and 15 borderline tumors were evaluated. One hundred thirty-three patients had ovarian carcinoma. In 76 cases (55%), the International Federation of Gynecology and Obstetrics stage was III or IV. Borderline tumors (n = 15) were excluded from the statistical calculations. CA 125 antigen was the most sensitive marker for ovarian carcinoma (81%). The highest specificity and positive predictive value was obtained with CA 15-3 antigen (95% and 92%, respectively). Considering a concomitant elevation of all 3 markers as positive, a positive predictive value of 97% was found. However, only 28% of the patients in the total group and 41% of the patients with ovarian carcinoma had a concomitant elevation of all 3 markers. The combination of all 3 markers with levels below the cut-off resulted in a (false-positive) positive predictive value for malignancy between 12% and 36%. With the use of logistic regression analysis, we found a correct prediction in 73% of the cases. CA 15-3 antigen makes the most significant (P.0001) contribution to the logistic model in the prediction of malignancy in the total group, with all pelvic masses with an odds ratio of 3.86.The combination of a simultaneous elevated level of CA 125, CA 15-3, and CA 72-4 antigens was predictive for malignant disease in almost all cases. However, such concomitant elevation was found in few of the malignant masses. Logistic regression analysis revealed that CA 15-3 antigen makes the most significant contribution to a model for the prediction of malignancy in the total group. The logistic model gave a correct prediction in 73% to 83%. The present tumor marker panel seems inferior to combinations with other test modalities, which include ultrasonography and/or physical examination and/or menopausal status or age.
-
8
المؤلفون: R. van der Sijde, Jan J. Jobsen, J.H. Meerwaldt, Eltjo M.J. Schutter, L. Naudin ten Cate, J. van der Palen
المساهمون: University of Twente
المصدر: International journal of gynecological cancer, 11(1), 49-53. Wolters Kluwer Health
مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.medical_treatment, Treatment results, Systemic therapy, Gastroenterology, Internal medicine, medicine, Carcinoma, Humans, Stage iib, Neoplasm Invasiveness, Stage (cooking), Aged, Neoplasm Staging, Aged, 80 and over, Pathologic stage, business.industry, Obstetrics and Gynecology, Middle Aged, medicine.disease, Combined Modality Therapy, Survival Analysis, Endometrial Neoplasms, Treatment Outcome, IR-102189, Female, Vaginal vault, Neoplasm Recurrence, Local, business, Adjuvant, Follow-Up Studies
الوصف: The aim of this study is to report survival and results of therapy and possible prognostic factors in women with pathologic stage II endometrial carcinoma. Forty-two patients with pathologic stage II endometrial carcinoma were treated at the department of Radiation Oncology of the Medisch Spectrum Twente between 1987 and 1998. All patients received external radiotherapy following standard surgical procedures and no adjuvant systemic therapy was given. From the 42 patients 21 had a pathologic stage IIA and 21 stage IIB. The median follow-up was 62 months. The overall recurrence rate was 21.5% (9/42). Seven patients had distant metastasis, of which three also had locoregional recurrence, vaginal vault and/or pelvic. The presence of myometrial invasion ((1/2)) and/or lymph-angioinvasion showed a significant relation with distant metastasis (P = 0.017). Stage IIB showed more recurrences, 33% (7/21). There was a significant different 5-year disease specific survival for stage IIA and IIB, respectively, 95% and 74% (P = 0.0311). Patients with a differentiation grade 3 and stage IIB showed a significantly poorer (P = 0.003) 5-year survival of 48.6% (P = 0.003). Results obtained in the present series of patients are in accordance with the literature. The present treatment policy seems justified, except for patients with pathologic stage IIB and grade 3, in which a more aggressive treatment should be considered.
-
9
المؤلفون: Eltjo M.J. Schutter, J.M Bolt
المصدر: European Journal of Obstetrics & Gynecology and Reproductive Biology. 76:233-236
مصطلحات موضوعية: medicine.medical_specialty, medicine.diagnostic_test, business.industry, Ultrasound, Obstetrics and Gynecology, Histopathological examination, medicine.disease, Surgery, Benign tumor, medicine.anatomical_structure, Vaginal disease, Leiomyoma, Reproductive Medicine, Biopsy, Vagina, medicine, Presentation (obstetrics), business
الوصف: A tumor in the paracolpium is very rare and generally only discovered by chance. In our patient, a leiomyoma was found. Only a few reports on this localisation have been published in the literature. Due to the variable clinical presentation of a leiomyoma of the vagina, it is difficult to differentiate between a malignant and a benign tumor. To discriminate between malignant and benign tumors, and to assess the surrounding structures, ultrasound, puncture and/or biopsy and CT-scan are the most common additional diagnostic techniques. However, in most cases, diagnosis is only made after histopathological examination. In our case report, the tumor was located in the upper part of the paracolpium and had no direct relation to the vagina. Surgical extirpation of the tumor was uneventful. Surgery is the recommended treatment.
-
10
المصدر: Tumor Biology. 18:274-277
مصطلحات موضوعية: medicine.medical_specialty, medicine.drug_class, Urinary system, Urinary gonadotropin peptide, Peptide, Urine, Biology, Pregnancy, Internal medicine, Biomarkers, Tumor, medicine, Humans, Chorionic Gonadotropin, beta Subunit, Human, Tumor marker, chemistry.chemical_classification, Analysis of Variance, Temperature, Cancer, General Medicine, medicine.disease, Peptide Fragments, Endocrinology, chemistry, embryonic structures, Female, Tissue Preservation, Gonadotropin
الوصف: In this report, we evaluate the stability of urinary gonadotropin peptide (UGP), an urinary tumor marker for trophoblastic malignancies, which is also promising for other types of cancer. The concentrations were independent of the duration of storage (p0.1), but the mean difference between UGP values for samples stored at 4 degrees C and those kept at room temperature is 5.5% (p0.002), with the higher values for refrigerated samples. We conclude that UGP is stable at room temperature, allowing mailing of urine samples. Refrigerated (4 degrees C) samples show slightly increased values. However, this will have no clinical relevance in monitoring cancer patients.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::576d131854e612cb837a5fe117ae1052
https://doi.org/10.1159/000218040
Full Text via ClinicalKey